|
Related Companies
|
[]
|
||||||||
|
Related Funds
|
[]
|
||||||||
|
|
|||||||||
|
English
|
|||||||||
|
oda_NoncurrentFinancialAssetAcquisitionAbstract|
|
|
||||||||
|
oda_UpdateAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_CorrectionAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_DateOfThePreviousNotificationAboutTheSameSubject|
|
|
-
|
|||||||
|
oda_DelayedAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
|
oda_AnnouncementContentSection|
|
|
||||||||
|
oda_BoardDecisionDateForAcquisition|
|
|
|
|||||||
|
oda_WereMajorityOfIndependentBoardMembersApprovedTheBoardDecisionForAcquisition|
|
|
-
|
|||||||
|
oda_TitleOfNoncurrentFinancialAssetAcquired|
|
|
Invios Holding AG
|
|||||||
|
oda_FieldOfActivityNoncurrentFinancialAssetWhoseSharesWereAcquired|
|
|
Biotechnology
|
|||||||
|
oda_CapitalOfNoncurrentFinancialAsset|
|
|
35000 EUR
|
|||||||
|
oda_AcquirementWay|
|
|
Kuruluşta Edinim (Establishment)
|
|||||||
|
oda_DateOnWhichTheTransactionWasWillBeCompleted|
|
|
-
|
|||||||
|
oda_AcquisitionConditions|
|
|
Diğer (Other)
|
|||||||
|
oda_DetailedConditionsIfItIsATimedPayment|
|
|
-
|
|||||||
|
oda_NominalValueOfSharesAcquired|
|
|
198 EUR
|
|||||||
|
oda_PurchasePricePerShare|
|
|
0
|
|||||||
|
oda_TotalPurchasingValue|
|
|
0
|
|||||||
|
oda_RatioOfNewSharesAcquiredToCapitalOfNoncurrentFinancialAsset|
|
|
0,566
|
|||||||
|
oda_TotalRatioOfSharesOwnedInCapitalOfNoncurrentFinancialAssetAfterTransaction|
|
|
0,566
|
|||||||
|
oda_TotalVotingRightRatioOwnedInNoncurrentFinancialAssetAfterTransaction|
|
|
0,566
|
|||||||
|
oda_RatioOfNoncurrentFinancialAssetAcquiredToTotalAssetsInLatestDisclosedFinancialStatementsOfCompany|
|
|
-
|
|||||||
|
oda_RatioOfTransactionValueToSalesInLatestAnnualFinancialStatementsOfCompany|
|
|
-
|
|||||||
|
oda_EffectsOnCompanyOperations|
|
|
Positive Impact is expected
|
|||||||
|
oda_DidTakeoverBidObligationArised|
|
|
Hayır (No)
|
|||||||
|
oda_WillExemptionApplicationBeMadeIfTakeoverBidObligationArised|
|
|
Hayır (No)
|
|||||||
|
oda_TitleNameSurnameOfCounterParty|
|
|
-
|
|||||||
|
oda_IsCounterPartyARelatedPartyAccordingToCMBRegulations|
|
|
Hayır (No)
|
|||||||
|
oda_RelationWithCounterPartyIfAny|
|
|
-
|
|||||||
|
oda_AgreementSigningDateIfExists|
|
|
|
|||||||
|
oda_ValueDeterminationMethodOfNoncurrentFinancialAsset|
|
|
-
|
|||||||
|
oda_DidValuationReportBePrepared|
|
|
Düzenlenmedi (Not Prepared)
|
|||||||
|
oda_ReasonForNotPreparingValuationReportIfItWasNotPrepared|
|
|
Not Obligatory
|
|||||||
|
oda_DateAndNumberOfValuationReport|
|
|
-
|
|||||||
|
oda_TitleOfValuationCompanyPreparedReport|
|
|
-
|
|||||||
|
oda_ValueDeterminedInValuationReportIfExists|
|
|
-
|
|||||||
|
oda_ReasonsIfTransactionWasntWillNotBePerformedInAccordanceWithValuationReport|
|
|
-
|
|||||||
|
oda_ExplanationSection|
|
|
||||||||
|
oda_ExplanationTextBlock|
|
-Unofficial Translation- Our company has been informed that the efforts to establish a new company called Invios Holding AG, by demerger of Apeiron Biologics AG which our company has 0,566% shares, have been completed in order to increase the operational efficiency and to carry out the project studies more effectively. Shareholders of this company will be existing shareholders of Apeiron Biologics AG. Within this scope our company became 0,566% shareholder of the Invios Holding AG. |
||||||||